Research Institute in Oncology and Hematology

Sabine Mai

Genomic Instability

Professor Physiology, Biochemistry & Medical Genetics, Human Anatomy and Cell Science
Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD)

Degrees:
B.Sc. in Biology, Univ. of Cologne, Germany, 1981
M.Sc. in Biology, French & Pedogogics, Univ. of Cologne, Germany, 1985
Ph. D. in Molecular Biology, Univ of Karlsruhe, Germany, 1991

Contact:
6046-675 McDermot Ave
Winnipeg, Mb R3E 0V9
(204) 787-2135
Dr Sabine Mai PhD

Awards

2015 WXN Top 100: Canada’s Most Powerful Women
2014 YMCA Women of Distinction Nominee
2013 Cognition Challenge Award
2006 Merit Award for Research and Training - University of Manitoba
2004 Breast cancer in three dimensions Research Award - US Army Breast Cancer Concept Award
2001 University of Manitoba Outreach Award - University of Manitoba
2000-2003 Manitoba Medical Services Foundation Basic Science Career Development Award
2000 Rh Award - Rh Institute Canada
1995-1996 NCIC Award for New Investigators
1995-1996 Braidwood Jackson Memorial Research Award - Braidwood Jackson Canada
1986-1987 DAAD Research Award - DAAD Germany
1980-1981 Bafoeg Research Award - Bafoeg Germany
1978-1985 Bafoeg Research Award - Bafoeg Germany

Funding

Investigator: Sabine Mai
Sponsor: Cancer Research Society / CancerCare Manitoba Foundation
Project: Disease progression in myeloma
Funds authorized: $ 60,000/annum (2016-2018)

Investigator: Sabine Mai
Sponsor: CancerCare Manitoba Foundation
Project: Nuclear remodeling in Hodgkin’s lymphoma
Funds authorized: $ 60,000/annum (2016-2018)

Investigator: Sabine Mai
Sponsor: Ride for Dad
Project: Profiling prostate cancer CTCs
Funds authorized: $ 150,000/annum (2015-2016)

Investigator: Uri Tabori
Co-Investiagtor: Sabine Mai
Sponsor: CCSRI – Impact grant, co-funded by Brain Canada
Project: Targeting the telomere maintenance pathway for cancer diagnostics and therapeutics
Funds authorized: $ 249,953/annum (2015-2020)

Investigator: Sabine Mai
Sponsor: Cancer Research Society
Project: Genetic profiling of disease progression in myeloma
Funds authorized: $ 120,000 (2014-2016)
Investigator: Sabine Mai
Sponsor: CancerCare Manitoba Foundation
Project: New mechanism of genomic instability?
Funds authorized: $ 60,000 (2014-2015)

Investigator: Sabine Mai
Sponsor: Canadian Cancer Research Institute (CCSRI)
Project: Nuclear architecture in cancer
Funds authorized: $ 99,999 (2014-2015); $ 98,211 (2015-2016)

Investigator: Sabine Mai
Sponsor: Ride For Dad
Project: Profiling prostate cancer CTCs
Funds authorized: $ 90,000 (2014-2015)

Investigator: Sabine Mai
Sponsor: CCMB
Project: Laser microdissection microscope
Funds authorized: $ 160,000 (2013-2014)

Investigator: Sabine Mai
Sponsor: Johnson and Johnson Innovation; Cognition Challenge Winner
Project: 3D nuclear telomere imaging in Alzheimer's disease
Funds authorized: $ US 50,000 (2013-2014)

Investigator: Sabine Mai
Sponsor: Brain Tumor Foundation of Canada
Project: Characterization of ependymoms into favourable and unfavourable groups based on their 3D nuclear telomeric profiles.
Funds authorized: $ 25,000 (2013-2014)

Investigator: Sabine Mai
Sponsor: Ride For Dad
Project: Profiling prostate cancer CTCs
Funds authorized: $ 55,000 (2013-2014)

Investigator: Sabine Mai
Sponsor: Movember
Project: GAP1 CTC project - Manitoba section
Funds authorized: $ 67,210 (2012-2014)

Investigator: Sabine Mai
Sponsor: Canada's Ride for DAD
Project: Prostate Cancer Research Grant - Genomic profiles of circulating tumor cells
Funds authorized: $50,000.00 (2012-2013)

Investigator: Donna Wall
Co-Investigators: Sabine Mai, Hans Knecht
Sponsor: Leukemia and Lymphoma Society of Canada
Project: 3D telomere structure a biomarker in Hodgkin's lymphoma
Funds authorized: $112,500.00 (2012-2014)

Investigator: Sabine Mai
Sponsor: CIHR
Project: The impact of 3D chromosome and gene positions in cancer
Funds authorized: $137,068/annum (2012-2017)

Investigator: Sabine Mai
Sponsor: U of Manitoba
Project: Core Molecular Imaging Platform
Funds authorized: $60,000/annum (2012-2017)

Investigator: Sabine Mai
Co-Investigator: Ade Olujunghbe
Sponsor: CancerCare Manitoba
Project: 3D telomere organization of MGUS and MM
Funds authorized: $60,000/annum (2012-2014)

Investigator: Sabine Mai
Sponsor: CIHR RPP
Project: The impact of 3D nuclear chromosome and gene positions on cancer
Funds authorized: $114,000/annum (2012-2014)

Investigator: Sabine Mai
Sponsor: Terry Fox Research Institute - hot opportunity fund
Project: 3D nuclear telomeric profiles at the transition from MDS/AML
Funds authorized: $50,000 (2012-2013)

Investigator: Sabine Mai
Co-Investigator: Ade Olujunghbe
Sponsor: Myeloma Canada
Project: 3D telomere organization in multiple myeloma
Funds authorized: $50,000 (2012-2013)

Investigator: Uri Tabori, Cynthia Hawkins, Sabine Mai
Sponsor: CIHR
Project: Prediction and prevention of glioma recurrence by targeting telomere dependent self-renewal capacity of tumor initiating cells
Funds authorized: $ 151,469/annum (2011-2016)

Investigator: Sabine Mai
Sponsor: CFI
Project: 3D nano-BioMedical Imaging Node
Funds authorized: $ 3, 065,159 (2009-2014)

Investigator: Sabine Mai
Sponsor: CCMB
Project: The fate of the Reed Sternberg cell
Funds authorized: $ 60,000/annum (2010-2012)

Investigator: Sabine Mai
Sponsor: CCMF
Project: Analysis of Gene Cluster Related to Accelerated Plasmacytoma Susceptibility
Funds authorized: $60,00/annum (2009-2010)

Investigator: Sabine Mai
Sponsor: CIHR
Project: Mechanisms and consequences of 3D telomere remodeling in cancer
Funds authorized: $129,610/annum (2009-2012)

Invited Seminars and Presentations at Symposia and Meetings 2009 - 2014

119) Hodgkin's lymphoma cells rearrange their genome through breakage-bridge-fusion cycles. AACR, Denver, 2009. (Amanda Guffei, Hans Knecht, Sabine Mai).
120) Anti-estrogen resistant breast cancer cells differ in their 3-dimensional chromosomal arrangements from their parental cells. AACR, Denver, 2009 (Johannes von Vopelius-Feldt, Andreea Nistor, Sabine Mai, Sabine Hombach-Klonisch).
121) Nuclear architecture in human thyroid carcinoma revealed by three-dimensional (3D) telomere imaging: New insight into genomic instability and potential diagnostic application. AACR, Denver, 2009. (Thomas Klonisch, Landon Wark, Sabine Hombach-Klonisch, Cuong Hoang-Vu, Sabine Mai)
122) Telomere-poor 'ghost' nuclei define Reed-Sternberg cells as end-stage cells. AACR, Denver, 2009 (Sawan B, Lichtenzstejn Z, Lichtenzstejn D, Mai S, Knecht H.)
123) Nuclear remodeling in cancer. CLL Meeting, Oct 2, 2009, Winnipeg.
124) Three-dimensional (3D) nuclear remodeling in cancer cells. Queen's University, Kingston. October 2009.
125) Nuclear remodeling in cancer. Fox Chase Cancer Center, Philadelphia, USA. November 2009.
126) Nuclear remodeling in cancer. McGill, Montreal, Quebec. December 2009.
127) Novel automated three-dimensional genome scanning tool based on the nuclear architecture of telomeres. Ludger Klewes, Nir Katzir, David Rourke, Yuval Garni, Sabine Mai. Waikiloa, Hawaii, February, 2010
128) Tumor initiation and progression of thyroid cancer impacts on telomeres as shown by three-dimensional (3D) imaging. Landon Wark, Sabine Hombach-Klonisch, Sheue-yann Cheng, Sabine Mai, Thomas Klonisch, Waikiloa, Hawaii, February 2010.
129) La reorganization des telomeres et des chromosomes dans le cancer. 27th Annual ACQ meeting, key note speaker, Montreal, April 2010.
130) Changement structural et nucleaire des telomeres dans la leucemie myeloide chronique (Samassekou O, Mai S, Hebert J, Yan J). 27th Annual ACQ meeting. Montreal, April 2010.
131) Effets des agents endommagent l'AND sur l'architecture nucleaire des telomeres (Samassekou O, Bastien N, Mai S, Yan J, Drouin R.) 27th Annual ACQ meeting. Montreal, April 2010.
132) Nuclear remodeling in cancer. Sabine Mai. 7th Canadian Symposium of Telomeres and Telomerase, McMaster University, Hamilton. May 2010.
133) Samassekou O, Mai S, Yan J. The alternative lengthening of telomeres alters the nuclear architecture and causes damage at telomeres. 7th Canadian Symposium of Telomeres and Telomerase, McMaster University, Hamilton. May 2010.
134) Knecht H, Sawan B, Mai S. 3D telomere dynamics in Hodgkin's lymphoma: a patient based molecular study. 7th Canadian Symposium of Telomeres and Telomerase, McMaster University, Hamilton. May 2010.
135) Gadji M, Fortin D, Tsanaclis AM, Yan J, Reddy JJ, Klonisch T, Drouin R, Mai S. Cellular mechanisms of recurrence in oligodendrogliomas. 7th Canadian Symposium of Telomeres and Telomerase, McMaster University, Hamilton. May 2010.
136) Danescu A, Di Cristofano A, Mai S, Hombach-Klonisch S. Alterations in the 3D nuclear organization of telomeres - an early step in endometrial carcinoma development. 7th Canadian Symposium of Telomeres and Telomerase, McMaster University, Hamilton. May 2010.
137) Glogowska A, Suthiphongchai T, Leelawat K, Jinawarth A, Mai S. Decreased numbers of telomeres in patients with bile duct cancer.
138) Klewes L, Katzir N, Rourke D, Garini Y, Mai S. Novel automated three-dimensional genome scanning based on the nuclear architecture of telomeres. 7th Canadian Symposium of Telomeres and Telomerase, McMaster University, Hamilton. May 2010.
139) Kongruttanachok N, Sawan B, Mai S, Knecht H. Characterization of the 3D nuclear telomere organization in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease. 7th Canadian Symposium of Telomeres and Telomerase, McMaster University, Hamilton. May 2010.
140) Martin LD, Harizanova J, Zhu G, Belch A, Mai S, Pilarski L. Cancer-specific nuclear positioning of translocation prone gene loci in non-malignant B-cells from patients with multiple myeloma. 52nd ASH Meeting, Orlando, Florida, December 2010.
141) Lajoie V, Lemieux B, Sawan B, Lichtensztejn D, Lichtensztejn Z, Rowe M, Wellinger R, Mai S, Knecht H. The Epstein-Barr Virus (EBV) Encoded Oncoprotein LMP1 Mediates Down Regulation of Shelterin Proteins, Formation of Telomere Aggregates and Multinuclearity. 52nd ASH Meeting, Orlando, Florida, December 2010.
142) Knecht H, Kongruttanachok N, Sawan B, Lichtensztejn Z, Lichtensztejn D, Mai S. 3D Telomere Dynamics in Hodgkin's lymphoma. 52nd ASH Meeting, Orlando, Florida, December 2010.
143) Glogowska A, Mai S, McAvoy E, Garcia A. Alzheimer's disease patients' telomere intensity differs from controls: pilot study results. 10th international conference on Alzheimer's and Parkinson's disease. Conference. Barcelona, Spain. March 9-13, 2011.
144) Kongrattanachok N, Knecht H, Mai S. Characterization of telomere dysfunction in Hodgkin's lymphoma. Orlando, Florida. AACR. April 2011.
145) Danescu A, Di Cristofano A, Mai S, Hombach-Klonisch S. 3D nuclear organization of telomeres during endometrial carcinoma development. Orlando, Florida. AACR. April 2011.
146) Mai S. 3D nuclear telomeric organization in circulating tumor cells isolation by filtration methods. NCIC-CTG; CTC workshop Toronto. April 2011.
147) N. Benali-Furet, F. Ye, J. Wechsler, S. Mai, D. Lichtensztejn, P. Bigel, A. Carlotti, MF Avril, F. Boitier, A. Pigné, P. Langlois, Y. Cayre. Comparative study of circulating tumor cells (CTCs) versus primary tumors using ScreenCell technology, a rapid and save method of CTC selection based on size. CTC conference. Prague. June 2011.
148) Mai S. Telomere-driven cancer cell diagnostics. Lorus Therapeutics. Toronto, July 2011.
149) Kuzyk A, Schmaelter A, Mueller S, Mai S. Nuclear localization and telomere length of chromosome 11 in mouse plasmacytoma. Canadian Cancer Research Conference. Toronto. November 2011.
150) Gadji M, Awe, JA, Rodriguez P, Oliveira FM, Mai S. Three-Dimensional Nuclear Telomeric Architecture Profiling Defines Cytopenias of Myelodysplastic Syndrome and its Transformation to Acute Myeloid Leukemia. Canadian Cancer Research Conference. Toronto. November 2011.
151) Gadji et al. 3D telomere profiles define patient subpopulations in MDS and AML. AACR. Chicago. March/April 2012.
152) Mai S. 3D telomere profiles define CTC subpopulations. 4th world summit on circulating tumor cells. Berlin, Germany. April 2012.
153) Gadji et al. Profiling three-dimesnional nuclear telomeric architecture of myelodysplastic syndrome and acute myeloid leukemia. 1st Symposium on Genome Stability and Telomeres. London, Ontario. May 2012.
154) Kuzyk and Mai. Individual telomere length aberrations in mouse plasmacytoma support a chromosome-specific protective mechanism. 1st Symposium on Genome Stability and Telomeres. London, Ontario. May 2012.
155) Wark et al. Nuclear architecture in thyroid carcinoma revealed by three-dimensional (3D) telomere imaging: New insight into genomic instability and potential diagnostic application.1st Symposium on Genome Stability and Telomeres. London, Ontario. May 2012.
156) Klewes et al. 3D telomeric profiles of MGUS, SMM, MM and relapsed MM. 1st Symposium on Genome Stability and Telomeres. London, Ontario. May 2012.
157) Mai S. 3D nuclear telomere parameters define CTC subpopulations. CTC Conference. Boston, MA. November 2012.
158) Mai S. 3D telomeric profiles. Invited presentation at Applied Spectral Imaging (ASI), Yokneam, Israel. January 2013.
159) Morato F, Gadji M, Simbes BP, Rego EM, Falcao RP, Mai S. Three-dimensional nuclear organization of chronic myeloid leukemia patients predicts accelerated phase and blast crisis. AACR/JCA, Maui, February 2013.
160) Mai S, Gadji M, Awe JA, XU MC, Kongruttanachok N, Knecht H. Measuring the three-dimensional nuclear architecture to detect cancer cells and cancer cell subpopulations. AACR/JCA, Maui, February 2013.
161) Samassekou O, Cappelletti V, Mai S. 3D nuclear organization of telomeres in breast cancer: towards a new approach to categorize breast cancer. AACR/JCA, Maui, February 2013.
162) Kuyzk A and Mai S. Cytoband 11E2 and 17q25 are lilnked to tumor aggressiveness. AACR/JCA, Maui, February 2013.
163) Sunpaweravong P, Thongwatchara P, Mai S. Three-dimensional nuclear telomere organization in advanced non-small cell lung cancer patients and its correlation with epidermal growth factor receptor mutational status. AACR/JCA, Maui, February 2013.
164) Mai S. 3D telomere profiling in cancer. Tartu University, Estonia. March 2013.
165) Samassekou O, Jan Y, Mai S. The alteration of the telomeric nuclear architecture and imbalance in length of individual telomeres are features of alternative lengthening of telomeres. Human Genetcis Meeting Montreal. April 2013.
166) Mai S. Characterization of CTCs and CTC subpopulations by quantitative molecular imaging. World CTC Meeting. Berlin. April 2013.
167) Mai S. Deep insights into the 3D nuclear organization in tumors. Dublin, ECA 2013. June 2013.
168) Mai S. 3D organization of the interphase nucleus in normal, immortalized and tumor cells. Dublin, ECA 2013. June 2013.
169) Mai S. 3D nuclear telomere imaging in Alzheimer's disease. Cognition Challenge Forum. San Francisco, July 2013.
170) Mai S. 3D nuclear telomere profiles in Alyheimer's disease. Canadian Consulate San Francisco, November, 2013.
171) Mai S. 3D nuclear telomere profiles in Alyheimer's disease. Johnson & Johnson Innovation centre, Menlo Park, Palo Alto, November, 2013
172) Mai, S. 3D nuclear telomere parameters define CTC subpopulations. World CTC coference, Boston, USA, November 2013.
173) Mai, S. Cancer, oncogenes, genomic instability. University of Skövde, Sweden, December 2013.
174) Mai, S. 3D nuclear organization, genome (in)stability and cancer. University of Skövde, Sweden, December 2013.
175) Mai, S. 3D nuclear organization, genome (in)stability and cancer. University of Gothenburg, Sweden, December 2013.
176) Mai S. 3D nuclear profiles of CTCs in intermediate risk prostate cancer patients. World CTC Meeting, Berlin, Germany, February 2014.
177) Awe JA, Yan A, Shah N, KlewesL, Kuzyk A, Xu M, Boles R, Saranchuk J, Drachenberg D, Mai S. 3D nuclear telomeric signatures define circulating tumor cells (CTCs) and characterize CTC sub-populations in intermediate risk prostate cancer patients. AACR, San Diego, April 2014.
178) Mai S. Genomic instability and telomere dysfunction. 2nd Canadian Symposium of Teloemres and Genome Integrity. Québec, May 2014.

Professional Activities

  1. External grant reviewer for NSERC, MRC, MHRC, CIHR, Valorisation Recherche Québec, NCIC, MMSF
  2. External referee for Proc. Natl. Acad. Sci (USA), Oncogene, J. Cell Physiol., Gene, Mol. Cell. Biol., Experimental Cell Research, Genes, Chromosomes and Cancer, JCB, J Pathol, Cancer Research
  3. Manitoba Institute of Cell Biology, Recruitment Committee, 1996-present
  4. Department of Immunology, Recruitment Committee, 1999-present
  5. Manitoba Institute of Cell Biology Animal Care Committee, 1997-present
  6. Reviewer of MRC National Graduate Students Research Poster Competition, 1999
  7. Reviewer of Manitoba Student Poster Competition, Research Day, 2000, 2001.
  8. Genomic Centre for Cancer Research and Diagnosis: User Committee: 2001-present
  9. CIHR Strategic Training Program "Innovative Technologies in Multidisciplinary Health Research training" selection committee: 2002-2009
  10. CIHR Strategic Training Program "Innovative Technologies in Multidisciplinary Health Research training" Annual Review Committee: 2003-2009
  11. CIHR Fellowship - Post- Ph.D. (FPF) committee: 2002-2006
  12. Member of the University of Manitoba Senate: 2003-2006
  13. Panel J Member NCIC: 2005-2008
  14. Judge of National Poster Competition, Research Day, Winnipeg, Manitoba, 2006, 2007
  15. Advisory Board Member, Industrial Technology Centre, Virtual Reality Centre, 2007-present
  16. Guest editor, Seminars in Cancer Biology (2007); " Non-random genomic instability in cancer: a fact not an illusion"
  17. Canadian Breast Cancer Research Alliance IDEA grants, review panel 2007
  18. Host of 6th Canadian Symposium of Telomeres and Telomerase at The Narrows Lodge, Lake Manitoba, May 2008
  19. CCSRI panel G, review panel member 2009-2011
  20. CIHR panel MCC, review panel member 2009-2011
  21. U of M Research Day on "Molecular Imaging". Co-organizer. 2009
  22. Organizing committee for the 7th Canadian Symposium of Telomeres and Telomerase, Hamilton, ON, May 2010.
  23. Organizing committee for the 1st Symposium on Genome Stability and Telomeres. London, Ontario. May 2012.
  24. CIHR panel CPT, review panel member 2012-
  25. CFI Leading Edge fund, expert panel review member 2012-



RIOH gratefully acknowledges the generous support of



CCMB_Logo RIOH is a joint institute of CancerCare Manitoba and University of Manitoba UofM_Logo